A Phase I/II, open-label, multicentre, dose escalation study assessing the safety and tolerability of pEYS606 when administered by electrotransfer (ET) in the ciliary muscle of patients with non infectious posterior, intermediate or panuveitis.

Administered By

Awarded By

Contributors

Start/End

  • October 6, 2017 - April 15, 2021